AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04768478 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: 25mg CBD ODTs (orally disintegrating tablet), with instructions to take CBD tablets t.i.d. (total of 50mg per dose t.i.d.) to be administered with routine post-operative pain management
Study NCT05400213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vallos
Description: Demineralized freeze-dried bone allograft (DFBA) in a small particle form
Study NCT05400213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vallomix
Description: A combination of cow-derived xenograft and human-derived DFDBA particulate
Study NCT05400213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vallos-F
Description: Demineralized freeze-dried bone allograft (DFDBA) in a fiber form
Study NCT05400213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vallomix-F
Description: A combination of cow-derived xenograft and human-derived DFDBA fibers
Study NCT04851964 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study NCT04851964 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT05091190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draws
Description: Blood draws will be realized at the following time points:~C1T1: at the baseline, before treatment administration. C1T2: cycle 1, after treatment administration. C2T1: the day of the 2nd cycle, before treatment administration. C2T2: the day of 2nd cycle, after treatment administration. C3T1: the day of the 3rd cycle, before treatment administration. C3T2: the day of 3rd cycle, after treatment administration.
Study NCT05943626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circadian Intervention
Description: The circadian intervention group will receive counseling and instruction to reduce evening and nighttime light exposure, increase morning room light and sunlight exposure, and to finish all food consumption at least 4 hours before bedtime.
Study NCT06295731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-106
Description: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)
Study NCT06295731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INBRX-106
Description: INBRX-106 by intravenous (IV) infusion, given every 3 weeks (QW3)
Study NCT06295731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
Study NCT06295731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
Study NCT04768478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually indistinguishable placebo ODTs, with instructions to take two tablets t.i.d., to be administered with routine post-operative pain management
Study NCT04005443 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: radiopharmaceutical
Description: his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
Study NCT05817773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: breastfeeding cradle
Description: Mothers with postop mobile cesarean section should be breastfed with a nursing cradle for 30 minutes every 2-3 hours, even if the baby does not cry, until after mobilization (for 6 hours after coming to the service) every time the baby cries.
Study NCT04869956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary pattern : High-fiber diet rich in PUFA
Description: High-fiber diet rich in PUFAs (total dietary intake of at least 30 grams of fiber per day, and of at least 3 grams of PUFAs per day from food, not supplements) at least 4 weeks before surgery
Study NCT04869956 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietary pattern: Standard diet
Description: standard nutritional recommendations
Study NCT05431582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: Given by PO 1 time a day with a glass (about 8 ounces) of water
Study NCT05431582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by vein over about 30-60 minutes on Day 1 of each cycle
Study NCT05431582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by vein over 30-60 minutes on Day 1 of each cycle.
Study NCT04667195 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment
Description: Within 4 hours of admission to the emergency department, clinical assessment will include:~* Demographics,~* comorbidity,~* symptoms,~* objective findings,~* triage at admission,~* blood test results,~* urine test results
Study NCT04930640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SGF200 group
Description: 1 times a day, 1 capsule for 1 time, before breakfast meal, for 8 week
Study NCT04930640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 week
Study NCT06348134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: A chemotherapy drug.
Study NCT06348134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab Injection
Description: A prescription medicine that is approved for use in combination with trastuzumab and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
Study NCT06348134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: A chemotherapy drug.
Study NCT06348134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: A medication used to treat breast cancer.
Study NCT06348134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: A medication used to treat breast cancer.
Study NCT06348134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: A hormone therapy drug.
Study NCT06418152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-modal treatment
Description: Multi-modal treatment was designed to target PD-specific declines in the areas of cognitive function and gait and posture impairments. MMT consists of simultaneously training a motor and cognitive task.
Study NCT06361277 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Reference Drug or Test Drug
Description: Tablet, Oral, QD for 1 Day, Washout period is more than 7 days after administration
Study NCT04650321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab at home
Description: Patients will receive ocrelizumab infusion at home.
Study NCT05515549 — intervention group
Intervention type: OTHER
Intervention: Venous blood was collected from patients under fasting state to detect the level of thrombus molecular markers
Description: The venous blood of the patients in fasting state was collected to detect the level of thrombus molecular markers. Color Doppler ultrasound was used as the gold standard to determine whether VTE occurred. According to the color Doppler ultrasound diagnosis results, the patients were divided into VTE group and non VTE group.
Study NCT05623605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moringa mouthwash
Description: using Moringa mouthwashes in 3 different concentrations (5,10,15%) twice per day for 7 days
Study NCT05623605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: star anise mouthwash
Description: using star anise mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
Study NCT05623605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indian costus mouth wash
Description: using Indian costus mouthwash in 3 different concentrations (5,10,15%) twice per day for 7 days
Study NCT05657743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of radioactive sources \[Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)\]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms
Study NCT05251935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Muscle Exercise Protocol
Description: Foot Muscle Exercise was given for 3 days per week for 40 minutes for the period of 6 months including home program
Study NCT05251935 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Arch Support Insole and One Leg Balance Activities
Description: Arch Support Insoles were provided that the child had to wear for 5 hours per day thrice weekly for 6 months plus performed one leg balance activities
Study NCT06289283 — intervention group
Intervention type: OTHER
Intervention: Urine samples and tissue samples: Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigera
Description: Samples for microbiome analysis:~Samples will be collected in clean leak-proof containers without disinfectant or detergent residue and with tight-fitting leak-proof lids and preserved in a refrigerator until be analyzed at the microbiology laboratory of TBRI.~Urine samples (50 ml) for microbiome analysis will be collected during cystoscopy examination. Samples will be stored at -80 °C until processing.~Tissue and urine samples from patients with bladder cancer: Under standard procedure of diagnostic cystoscopy urine sample will be collected under complete aseptic conditions, patients who has bladder tumor will undergo transurethral resection of bladder tumor, a tissue sample 0.5x0.5 cm will be investigated for microbiome analysis. Samples will be stored at -80 °C until processing. Histopathological diagnosis with Hematoxylin and eosin stain will be done by an expert pathologist for tumor grade and stage according to WHO 22, and EAU guidelines 2023. This procedure will be applied for
Study NCT05187910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech Therapy
Description: Training with a Speech Language Pathologists for voice disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
Study NCT05187910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallowing Therapy
Description: Training with a Speech Language Pathologists for swallowing disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
Study NCT04919993 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Insomnia
Description: Group presentation
Study NCT05568849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OCTA measurements
Description: OCTA images will be obtained from the retina at 1-3 time points around the time of children's heart surgery
Study NCT05187910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper Airway Therapy
Description: Training with a Speech Language Pathologists for upper airway disorders. This is typically done with an initial visit done jointly with an MD physician. Then there are 4 subsequent therapy visits in addition to home practice exercises. Finally there will be another joint post-treatment evaluation to determine progress and next steps.
Study NCT06375915 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radioembolization with Y-90
Description: Radioembolization with Y-90 will be performed in nominal day 0
Study NCT06490822 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Description: A single 3 mm-diameter punch skin biopsy will be obtained from FTLD patients and healthy volunteers at the C8 paravertebral under local anesthesia to analyze cutaneous innervation
Study NCT06375915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle
Study NCT06375915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
Study NCT06375915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle
Study NCT06262503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality device is used for creating 3d avatar to engage the patient into a virtual world so he can overcome his pain
Study NCT06262503 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS stimulation plays on pain gate theory it sends stimulation to close C-fibers to relieve the pain and make the patient comfortable. The electrodes were put around the stump leg (residual limb) and the session lasts for 15 minutes, the parameters were Conventional TENS - high frequency (50-100 Hz), low intensity, short pulse width (50-200 μs). Pain relief by means of the pain gate mechanism involves activation (excitation) of the A beta (Aβ) sensory fibers, and by doing so, reduces the transmission of the noxious stimulus from the 'c' fibers, through the spinal cord and hence on to the higher centers.
Study NCT06262503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: TENS stimulation plays on pain gate theory it sends stimulation to close C-fibers to relieve the pain and make the patient comfortable. The electrodes were put around the stump leg (residual limb) and the session lasts for 15 minutes, the parameters were Conventional TENS - high frequency (50-100 Hz), low intensity, short pulse width (50-200 μs). Pain relief by means of the pain gate mechanism involves activation (excitation) of the A beta (Aβ) sensory fibers, and by doing so, reduces the transmission of the noxious stimulus from the 'c' fibers, through the spinal cord and hence on to the higher centers.
Study NCT06262503 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mirroring Therapy
Description: Mirroring Therapy :it tricks the brain. By placing a mirror between the healthy limb and the missing limb, patients see a reflection of the healthy limb, essentially replacing the phantom limb with a visual representation. This visual feedback is thought to reactivate brain areas responsible for the missing limb, potentially restoring its representation and reducing the discomfort of PLP. Essentially it aims to heal the brain's image of the body, which might in turn alleviate the pain associated with the missing limb.
Study NCT06262503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirroring Therapy
Description: Mirroring Therapy :it tricks the brain. By placing a mirror between the healthy limb and the missing limb, patients see a reflection of the healthy limb, essentially replacing the phantom limb with a visual representation. This visual feedback is thought to reactivate brain areas responsible for the missing limb, potentially restoring its representation and reducing the discomfort of PLP. Essentially it aims to heal the brain's image of the body, which might in turn alleviate the pain associated with the missing limb.
Study NCT06262503 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Phantom Exercises
Description: The study investigated phantom exercises (PE) for phantom limb pain (PLP) relief. Patients performed specific foot and leg movements 15 times, stopping if PLP disappeared early. Exercises were repeated daily or upon PLP recurrence. Patients imagined their phantom limb position and mimicked it with their remaining limb, performing ankle, foot, knee, and hip movements until relaxation and PLP subsided.
Study NCT06262503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phantom Exercises
Description: The study investigated phantom exercises (PE) for phantom limb pain (PLP) relief. Patients performed specific foot and leg movements 15 times, stopping if PLP disappeared early. Exercises were repeated daily or upon PLP recurrence. Patients imagined their phantom limb position and mimicked it with their remaining limb, performing ankle, foot, knee, and hip movements until relaxation and PLP subsided.
Study NCT05056519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine
Description: Live Attenuated Influenza Vaccine placebo, containing H1, H3 and B type influenza Live Attenuated virus.
Study NCT05056519 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Live Attenuated Influenza Vaccine placebo
Description: Live Attenuated Influenza Vaccine placebo, not containing H1, H3 and B type influenza Live Attenuated virus.
Study NCT04715906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UP-Caregiver
Description: The Unified Protocol (UP) is a telehealth group session using Zoom with each session lasting approximately 60-90 minutes. The sessions will focus on a variety of Cognitive Behavior Therapy techniques. These sessions may include teaching coping skills, goal setting, parent-child problem solving and communication, and motivation during this pandemic.
Study NCT06253117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone Days 1-7: 267 mg PO TID (801 mg/day) Days 8-14: 534 mg PO TID (1602 mg/day) Day 15 and thereafter: 801 mg PO TID; not to exceed 2403 mg/day~Duration of treatment- total 6 months
Study NCT06253117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05907967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
Study NCT05907967 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VeNS
Description: The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.
Study NCT06212557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KIOS App
Description: KIOS provides patients on demand individualized advice and reinforcement of lifestyle interventions to improve self-management during Medication-Assisted Treatment (MAT)
Study NCT06212557 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: KIOS App education
Description: Educational tools provided to participants with opioid use disorder
Study NCT06212557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Behavioral counseling in clinic
Study NCT06212557 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treatment as usual
Description: Behavioral counseling in clinic
Study NCT06004531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompting open-ended question promoting sustainability
Description: This intervention will include active persuasion through prompting participants to answer an open-ended question regarding how they will alter their behavior to become more sustainable and eco-friendly.
Study NCT05336994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement A
Description: Oral administration of Supplement A
Study NCT06004531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainability Passage
Description: This intervention will include passive persuasion through presenting participants with a passage discussing the serious issue of climate change and the pressing need for systemic and individual change to adopt sustainable practices and lifestyles.
Study NCT05336994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement B
Description: Oral administration of Supplement B
Study NCT05414721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low flow desflurane anesthesia (Group D)
Description: When the MAC value of desflurane was 1, fresh gas flow was decreased to 0.5 L/min (60% O2+40% air). Hemodynamic parameters, SpO2 and BIS values were recorded after induction, at the beginning of low flow/normal flow anesthesia and every 5 minutes during surgery. The patients were observed in terms of side effects and complications during the operation and in the postoperative period. To research the liver and the kidney functions, blood samples were taken pre-induction, post-surgery, and at the postoperative 24th hour by venous route.
Study NCT04594603 — intervention group
Intervention type: OTHER
Intervention: Phacoemulsification for cataract
Description: Phacoemulsification for removal of cataract